Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25328611 | 0.92 | PTGS1 (0.42) | ESR1PTGS1PTGS2TP53ALOX5 | |
| SCHEMBL30356518 | 0.88 | ESR1 (0.45) | ESR1PTGS1PTGS2ALOX5RARB | |
| SCHEMBL25328680 | 0.88 | ESR1 (0.45) | ESR1PTGS1PTGS2ALOX5RARB | |
| SCHEMBL25328760 | 0.85 | ESR1 (0.40) | ESR1TP53ALOX5LTA4H | |
| SCHEMBL30356497 | 0.84 | TSHR (0.38) | ESR1TP53 | |
| SCHEMBL689246 | 0.84 | ESR1 (0.47) | ESR1PTGS1PTGS2TP53ALOX5 | |
| SCHEMBL30367452 | 0.84 | ESR1 (0.47) | ESR1PTGS1PTGS2TP53ALOX5 | |
| SCHEMBL5588257 | 0.81 | ESR1 (0.47) | ESR1PTGS1PTGS2ALOX5RARB | |
| SCHEMBL25329487 | 0.79 | PTGS1 (0.43) | ESR1PTGS1PTGS2TP53LTA4H | |
| SCHEMBL25328938 | 0.79 | PTGS1 (0.43) | ESR1PTGS1PTGS2TP53ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583813-B2 | Polymerization inhibitors | BASF SE (DE) | 2026-03-24 | — | — | US | disclosed |
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | BASF SE (DE) | 2023-08-03 | — | — | US | disclosed |
| CN-115697954-A | Polymerization inhibitor | 巴斯夫欧洲公司 | 2023-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242472-A1 | POLYMERIZATION INHIBITORS | RCE1, CABLES1, DPYD | ESR1 3959/4885PTGS1 474/4885PTGS2 594/4885 |
| US-12583813-B2 | Polymerization inhibitors | PTGS1, PTGER1, POT1 | ESR1 2282/4885PTGS1 1/4885PTGS2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.